Tryptase EQA
| Accreditation Status: | UKAS Schedule of Accreditation | ||||||||||
| Date Scheme started: | 2010 | ||||||||||
| Clinical Applicability: |
The serum tryptase concentration reflects both the clinical severity of the allergic reaction and the reaction mechanisms. Serum tryptase can also be utilised for determining suspected mastocytosis and suspected acute allergic reactions (SER/040) |
||||||||||
| Analytes: |
Tryptase |
||||||||||
| Units for Reporting: |
Quantitative responses (µg/L) |
||||||||||
| Samples Distributed: | Liquid format. Normal and pathological human serum | ||||||||||
| Number of Distributions per year: | 6 | ||||||||||
| Number of Samples per Distribution: |
2 |
||||||||||
| Frequency of Distributions: | Every two months as outlined in the Distribution Schedule | ||||||||||
| Schedule of Analysis: | Data entry is via the web for the submission of results. Data analysis commences 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics. | ||||||||||
| Data Analysis: |
All Laboratory Trimmed Mean (ALTM) with truncation at 2SD, SD and CV%. Reports show method specific statistics. Individual laboratory performance is expressed in terms of MRBIS, SDBIS and MRVIS Chosen Coefficient of Variation for Tryptase is 8% |
||||||||||
| Performance Scoring: | MRVIS | ||||||||||
| Criteria of Performance: |
Laboratory performance is classified in terms of the MRVIS over a running analytical window of 6 Distributions (12 months)
|
||||||||||
| Persistent Poor Performance: |
Defined as being in the Poor Performance category for two or more successive Distributions |